Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Prevalence of Coronavirus Disease 2019 in Patients With Neuromyelitis Optica in Isfahan, Iran, and a Review on Recent Reports and Literature Publisher



Etemadifar M1 ; Salari M2 ; Aminzade Z2, 3 ; Ebrahimi S4 ; Tehranifateh S2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. School of Medicine, Yazd University of Medical Sciences, Yazd, Iran

Source: Current Journal of Neurology Published:2021


Abstract

Background: Despite many studies, it is still unclear how patients with neuromyelitis optica spectrum disorder (NMOSD) would respond to coronavirus disease 2019 (COVID-19). We conducted a research on prevalence of COVID-19 in patients with NMOSD in Isfahan, Iran. We have also reviewed the recent publications on this issue. Methods: 149 patients with NMOSD who were under medications were monitored for confirmed cases of COVID-19. Prevalence of COVID-19 in addition to mean age, mean duration of disease, and mean age of onset of infected patients and uninfected patients were calculated via Microsoft Excel software. Results: The prevalence of COVID-19 in studied patients with NMOSD was 5.37%. Mean age, mean duration of disease, and mean age of onset of eight patients (male to female ratio: 1:3) diagnosed with COVID-19 were 33.62 ± 5.20 years, 6.87 ± 6.05 years, and 26.75 ± 6.94 years, respectively, while they were 39.97 ± 11.37 years, 7.50 ± 3.91 years, and 32.46 ± 11.29 years for uninfected patients with NMOSD (n = 141). No significant association was observed between the type of medications and prevalence of COVID-19 (P > 0.05). Conclusion: There is not a consensus in the literature on the prevalence of COVID-19 in patients with NMOSD and the effect of NMOSD medications on susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prevalence of COVID-19 in our sample was 5.37%. The impact of the kind of NMOSD medication on the prevalence of COVID-19 in patients with NMOSD was found to be insignificant. Moreover, the infected patients were relatively younger, and their disease started earlier in comparison to uninfected patients. © 2021 Iranian Neurological Association, and Tehran University of Medical Sciences Published by Tehran University of Medical Sciences.
Related Docs
View other Related Docs
1. Covid-19 Susceptibility and Outcomes Among Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
2. Post Covid-19 Infection Neuromyelitis Optica Spectrum Disorder (Nmosd): A Case Report-Based Systematic Review, Multiple Sclerosis and Related Disorders (2022)
3. The Impact of Covid-19 Pandemic on Neuromyelitis Optica Disorder Patients, After One Year, Caspian Journal of Neurological Sciences (2022)
4. Multiple Sclerosis (Ms) and Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccines: A Systematic Review, Revue Neurologique (2023)
5. Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (Nmosd) Five Years After Disease Onset, Journal of Clinical Medicine (2022)
6. Relapse-Independent Disease Activity in Neuromyelitis Optica Spectrum Disorder: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
7. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Covid-19: A Systematic Review, Journal of Central Nervous System Disease (2023)
8. Comparing the Consequences of Covid-19 Vaccination Between Central Nervous System (Cns) Demyelinating Diseases and Other Neurological Disorders, Vaccine (2024)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (38)
Fereshteh Ashtari (22)
Other Related Docs
9. Cns Demyelinating Disease Following Inactivated or Viral Vector Sars-Cov-2 Vaccines: A Case Series, Vaccine (2023)
10. Assessment of Mental Health, Knowledge, and Attitude of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Response to 2019 Novel Coronavirus, Neurological Sciences (2021)
11. Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder (Nmosd) in Iran: A Consensus Guideline and Recommendations, Multiple Sclerosis and Related Disorders (2017)
12. Neuromyelitis Optica Spectrum Disease Characteristics in Isfahan, Iran: A Cross-Sectional Study, Journal of Research in Medical Sciences (2017)
13. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
14. Disease Course, Progression and Activity of Neuromyelitis Optica (Nmosd) in Patients Who Were Treated With Rituximab, 6 and 12 Months After Receiving the First Dose of Drug, in Isfahan City, Multiple Sclerosis and Related Disorders (2019)
15. Retinal Findings of Covid-19 Patients Using Ocular Coherence Tomography Angiography Two to Three Months After Infection: Ocular Appearance Recovered Covid-19 Patient, Photodiagnosis and Photodynamic Therapy (2022)
16. The Correlation Between Rituximab Dose Reduction and Acute Relapses of Neuromyelitis Optica Spectrum Disorder, Lessons From Covid-19 Epidemic, Multiple Sclerosis and Related Disorders (2024)
17. Frequency of Comorbidities in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2021)
18. Worldwide Prevalence of Neuromyelitis Optica Spectrum Disorder (Nmosd) and Neuromyelitis Optica (Nmo): A Systematic Review and Meta-Analysis, Neurological Sciences (2023)
19. The Prevalence of Cognitive Impairment in Patients With Neuromyelitis Optica Spectrum Disorders (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
20. Guillain-Barre Syndrome in Patients With Coronavirus Disease-2019: Report of Six Cases and Review of Literature, Current Journal of Neurology (2020)
21. Predictors of Relapse Risk and Treatment Response in Aqp4-Igg Positive and Seronegative Nmosd: A Multicentre Study, Journal of Neurology, Neurosurgery and Psychiatry (2024)
22. Retinal Optical Coherence Tomography in Neuromyelitis Optica, Neurology: Neuroimmunology and NeuroInflammation (2021)
23. “Nmda Receptor Spectrum Disorder” in the Differential Diagnosis of Demyelinating Disorders of the Cns: Optic Neuritis and Myelitis, Neurological Sciences (2021)
24. Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With Aqp4-Igg-Positive Nmosd, Neurology (2024)
25. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
26. Comparative Study of Quality of Life, Anxiety, Depression, and Fatigue Among Patients With Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis: The First Report From Iran, Multiple Sclerosis and Related Disorders (2018)
27. Frequency of Diencephalic Syndrome in Nmosd, Acta Neurologica Belgica (2022)
28. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
29. The Association Between Dietary Inflammatory Index and Risk of Neuromyelitis Optica Spectrum Disorder: A Case–Control Study, Nutritional Neuroscience (2024)
30. Neuropsychiatric Manifestations of Covid-19 in Hospitalized Pediatrics: A Multicenter Cross-Sectional Study, Archives of Pediatric Infectious Diseases (2023)
31. The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica, Basic and Clinical Neuroscience (2021)
32. Differential Diagnostic Utility of Clinical Laboratory Data in Patients With Severe and Non-Severe Covid-19, Shiraz E Medical Journal (2022)
33. Cognitive Function and Brain Magnetic Resonance Imaging Profiles in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis, Journal of Research in Medical Sciences (2024)
34. Electrolyte Abnormalities in Hospitalized Covid-19 Patients at Tertiary Referral Centers in Tehran: Hypermagnesemia As a Marker of Fatality: A Retrospective Cross-Sectional Study, Health Science Reports (2023)
35. Higher Latitude Is Significantly Associated With an Earlier Age of Disease Onset in Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2016)
36. Comparison of the Efficacy of Azathioprine and Rituximab in Neuromyelitis Optica Spectrum Disorder: A Randomized Clinical Trial, Journal of Neurology (2017)
37. Acute Necrotizing Encephalopathy in Adult Patients With Covid-19: A Systematic Review of Case Reports and Case Series, Journal of Clinical Neurology (Korea) (2023)
38. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
39. Risk Factors, Clinical, and Laboratory Characteristics of Patients With a Diagnosis of Covid-19, Journal of Emergency Practice and Trauma (2022)
40. Association Between Helicobacter Pylori Infection and Seronegative Neuromyelitis Optica Spectrum Disorder, Caspian Journal of Neurological Sciences (2023)
41. Age-Dependent Clinical Features and Prognosis of Covid-19 Patients, Tanaffos (2021)
42. Relative Frequency of Primary Headaches in Patients With Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study, Current Journal of Neurology (2024)
43. The Covid-19 Pandemic: A Systematic Review of the Current Evidence; [Пандемия Covid-19: Систематический Обзор Современных Данных], Russian Journal of Infection and Immunity (2020)
44. Myasthenia Gravis and Covid-19: A Systematic Review and Meta-Analysis, Basic and Clinical Neuroscience (2024)
45. Myasthenia Gravis and Coronavirus Disease 2019: A Report From Iran, Current Journal of Neurology (2021)
46. Fulminant Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccination: A Need for Reconsideration?, Multiple Sclerosis and Related Disorders (2022)
47. Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders, Neurology: Neuroimmunology and NeuroInflammation (2024)
48. Neuromyelitis Optica Spectrum Disorder and Menstruation, Revue Neurologique (2018)
49. Case Report: Tumefactive Brain Lesions in Patients With Neuromyelitis Optica Spectrum Disorder, Caspian Journal of Neurological Sciences (2019)
50. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)